HESX1 mutations in patients with congenital hypopituitarism: variable phenotypes with the same genotype. (28th April 2016)

• Record Type: Journal Article
• Authors: Fang, Qing; Benedetti, Anna Flavia Figueredo; Ma, Qianyi; Gregory, Louise; Li, Jun Z.; Dattani, Mehul; Sadeghi‐Nejad, Abdollah; Arnhold, Ivo J.P.; Mendonca, Berenice Bilharinho; Camper, Sally A.; Carvalho, Luciani R.
• Is Part Of: Clinical endocrinology. Volume 85:Number 3(2016)
• Page Start: 408
• Page End: 414
• Publication Date: 2016-04-28
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.13067
• Languages: English
• ISSNs: 0300-0664

Abstract

Summary: Introduction: Mutations in the transcription factor HESX1 can cause isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiency (CPHD) with or without septo‐optic dysplasia (SOD). So far there is no clear genotype–phenotype correlation. Patients and Results: We report four different recessive loss‐of‐function mutations in three unrelated families with CPHD and no midline defects or SOD. A homozygous p.R160C mutation was found by Sanger sequencing in two siblings from a consanguineous family. These patients presented with ACTH, TSH and GH deficiencies, severe anterior pituitary hypoplasia (APH) or pituitary aplasia (PA) and normal posterior pituitary. The p.R160C mutation was previously reported in a case with SOD, CPHD and ectopic posterior pituitary (EPP). Using exome sequencing, a homozygous p.I26T mutation was found in a Brazilian patient born to consanguineous parents. This patient had evolving CPHD, normal ACTH, APH and normal posterior pituitary (NPP). A previously reported patient homozygous for p.I26T had evolving CPHD and EPP. Finally, we identified compound heterozygous mutations in HESX1, p.[R159W];[R160H], in a patient with PA and CPHD. We showed that both of these mutations abrogate the ability of HESX1 to repress PROP1‐mediated transcriptional activation. A patient homozygous for p.R160H was previously reported in a patient with CPHD, EPP, APH. Conclusion: These three examples demonstrate that HESX1 mutations cause variable clinical features in patients, which suggests an influence of modifier genes or environmental factors on the phenotype.